AgenT
Developing the first blood diagnosis to detect Alzheimer’s disease while it’s still in the silent phase.
- biotechnology
- horizon europe
- dt and ls
- core ai
- radar de l'innovation
- ai applications
- tech for business
- eit ecosystem
- observatoire industrial tech
- observatoire deeptech
- neurology
- surgery
- eit health
- biotech, medtech and e-health
- health it
- research and development
- physician support tools
- observatoire healthtech
- longevity
- medical diagnostics
- clinical decision support
- surgical equipment
- biomarkers
- health information
- european health catapult (eit health)
- alzheimers disease
- european health catapult 2020 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
€10.0k | Support Program | ||
| Total Funding | 000k | ||
Related Content
AgenT Biotech is at the forefront of Alzheimer's disease detection, utilizing advanced machine learning and multiomics technology to analyze proteins and metabolites in blood plasma. The company aims to arm physicians with a revolutionary blood test capable of identifying Alzheimer's up to 20 years before the onset of irreversible symptoms. This early detection is crucial for preventing or slowing the progression of the disease, which current diagnostic tools fail to achieve until it's too late.
AgenT Biotech primarily serves healthcare providers and researchers focused on neurodegenerative diseases. Operating within the biotech and healthcare markets, the company employs a business model centered on the development and commercialization of its proprietary blood test. Revenue is generated through the sale of diagnostic tests and potential partnerships with pharmaceutical companies for therapeutic development.
Keywords: Alzheimer's, early detection, blood test, machine learning, multiomics, biomarkers, healthcare, neurodegenerative, diagnostics, biotech.